The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
Open accessAbstract
OBJECTIVES: To measure the rate of progression in striatal [18F]dopa metabolism in a large group (n=32) of patients with Parkinson's disease, to estimate the average duration of preclinical period, and to examine the influence of the PET method on the assessment of rate of progression and preclinical period. METHODS: Thirty two patients with Parkinson's disease (mean age 58 (SD 13) years, mean duration 39 (SD 33) months) were assessed with [18F]dopa PET and UPDRS scoring on two occasions a mean of 18 (SD 6) months apart. PET data were sampled with separate caudate and putamen and total striatal regions of interest, and both graphical (Ki) and ratio methods of analysis. RESULTS: The mean annual rate of deterioration in [18F]dopa uptake varied according to structure and method of analysis, with putamen Ki showing the most rapid mean rate of progression (4.7% of normal mean per year). The group showed a significant deterioration (p<0.0004, paired two tailed t test) in UPDRS and in the putamen (p=0.008) and total striatal (p=0.012) [18F]dopa uptake measured using a graphical analysis, but no significant change in caudate or putamen uptake measured by a ratio approach. A study of sensitivity confirmed that putamen Ki was the most sensitive measure of disease progression, caudate ratio the least. Symptom onset in Parkinson's disease was estimated at a mean putamen [18F]dopa uptake (Ki) of 75% of normal and a mean caudate [18F]dopa uptake (Ki) of 91% of normal. CONCLUSIONS: Estimation of mean rate of progression varies according to the sensitivity of a functional imaging method to clinical severity. Sensitivity and reproducibility of method must be considered when designing studies of disease progression and neuroprotection. The mean preclinical period in Parkinson's disease is unlikely to be longer than seven years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
SCHEFFE, H. (1960) · Soil Science · doi:10.1097/00010694-196006000-00016 · Cited by 5,516
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Calculating correlation coefficients with repeated observations: Part 2—correlation between subjects
Bland, J. M., & Altman, D. G. (1995) · BMJ · doi:10.1136/bmj.310.6980.633 · Cited by 1,082
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease
Lees, A. J. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302969 · Cited by 491
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & William Langston, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366
Self-citationSnow, B. J., Tooyama, I., McGeer, E. G., Yamada, T., Calne, D. B., Takahashi, H., & Kimura, H. (1993) · Annals of Neurology · doi:10.1002/ana.410340304 · Cited by 336
BROOKS, D. J., SALMON, E. P., MATHIAS, C. J., QUINN, N., LEENDERS, K. L., BANNISTER, R., MARSDEN, C. D., & FRACKOWIAK, R. S. J. (1990) · Brain · doi:10.1093/brain/113.5.1539 · Cited by 256
Self-citationClinical and [18F] dopa PET findings in early Parkinson's disease.
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.6.597 · Cited by 245
Self-citationVingerhoets, F. J. G., Snow, B. J., Lee, C. S., Schulzer, M., Mak, E., & Calne, D. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360512 · Cited by 218
Guttman, M., Burkholder, J., Kish, S. J., Hussey, D., Wilson, A., DaSilva, J., & Houle, S. (1997) · Neurology · doi:10.1212/wnl.48.6.1578 · Cited by 174
Striatal function in normal aging: Implications for Parkinson's disease
Sawle, G. V., Colebatch, J. G., Shah, A., Brooks, D. J., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280611 · Cited by 159
Self-citationRegional changes in [18F]dopa metabolism in the striatum in Parkinson's disease
Morrish, P., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.6.2097 · Cited by 153
Self-citationWhen does Parkinson's disease begin?
Wc, K. (1992) · PubMed · Cited by 99
The effect of entacapone (OR‐611) on brain [ 18 F]‐6‐L‐fluorodopa metabolism
Sawle, G. V., Burn, D. J., Morrish, P., Lammertsma, A. A., Snow, B. J., Luthra, S. K., Osman, S., & Brooks, D. J. (1994) · Neurology · doi:10.1212/wnl.44.7.1292 · Cited by 95
Self-citationTakikawa, S., DHAWAN, V. M., Chaly, T., Robeson, W., Dahl, R. A., ZANZI, I., Mandel, F. S., Spetsieris, P. G., & Eidelberg, D. (1994) · PubMed · Cited by 84
Evaluation of the Short Parkinsonʼs Evaluation Scale
Rabey, J. M., Bass, H., Bonuccelli, U., Brooks, D. J., Klotz, P., Korczyn, A. D., Kraus, P., Martinez-Martin, P., Morrish, P., Sauten, W. V., et al. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199708000-00004 · Cited by 77
Self-citationReproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects.
Vingerhoets, F. J. G., Snow, B. J., Schulzer, M., Morrison, S., Ruth, T. J., Holden, J. E., Cooper, S. D., & Calne, D. B. (1994) · PubMed · Cited by 73
Merello, M., Sabe, L., Teson, A., Migliorelli, R., Petracchi, M., Leiguarda, R. C., & STARKSTEIN, S. E. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.12.1503 · Cited by 68
Vingerhoets, F. J. G., Schulzer, M., Ruth, T. J., et al. (1996) · PubMed · Cited by 57
AETIOLOGY OF PARKINSON'S DISEASE
Gibberd, F. B., Blair, J. A., Parveen, H., BARFORD, P. A., & Leeming, R. J. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90102-8 · Cited by 31
Pathophysiology of movement disorders studied using PET
Leenders, K. L. (1997) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6842-4_5 · Cited by 16
Cited by
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Self-citationSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citation
Metadata
- Authors
- Morrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 1998-03-01
- Volume
- 64
- Issue
- 3
- Pages
- 314-319
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2156177559
- Cited by
- 510
- References
- 27
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.